High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Investing.com -- Jefferies downgraded Cigna to Hold from Buy, arguing that a growing list of earnings headwinds and limited catalysts outweigh the stock's discounted valuation, while cutting its price target to $307 from $336.
The company published the arithmetic of its own margin repair, and the first hard proof landed a quarter before the shares started compounding.
Investing.com -- Raymond James downgraded Cigna Group to Outperform from Strong Buy and lowered its price target to $320 from $350, saying the health insurer's valuation remains attractive but near-term catalysts are lacking as growth moderates and its pharmacy benefit management (PBM) business faces ongoing headwinds. The brokerage said Cigna operates in a mature market with slower growth than other names under its coverage and expects continued investments in the PBM transition, combined with
The lever behind UnitedHealth stock's climb was a Medicare Advantage repricing management had described months before the run began, and the hard part was believing a plan whose author had just been wrong.
The Cigna Group recently reported past second-quarter 2026 results showing higher sales of US$67.03 billion, revenue of US$71.67 billion, and net income of US$1.66 billion, alongside increased earnings per share from continuing operations versus a year earlier. Alongside raising its full-year adjusted earnings outlook, Cigna continued capital returns through share repurchases and affirmed a quarterly dividend of US$1.56 per share, while pressing ahead with its rebate-free Signature pharmacy...
Cigna Group (NYSE:CI) raised its full-year 2026 adjusted earnings outlook after reporting second-quarter results that management said exceeded expectations in both its Evernorth health services business and Cigna Healthcare insurance segment. The company reported second-quarter total revenue of $71
The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.
Adjusted EPS of $7.78 beats expectations, leading to a full-year outlook increase to at least $30.45, as Specialty and Care Services surge 22%.
Cigna delivers an earnings and revenue beat as Cigna Healthcare fuels growth, while the company raises its 2026 EPS outlook despite higher pharmacy costs.
The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cigna (CI) delivered earnings and revenue surprises of +2.64% and +0.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Health insurance company Cigna (NYSE:CI) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 6.8% year on year to $71.67 billion. Its non-GAAP profit of $7.78 per share was 2.4% above analysts’ consensus estimates.
Investing.com -- The Cigna Group (NYSE:CI) reported second-quarter earnings and revenue that exceeded analyst expectations, while raising its full-year outlook, though shares fell 1% premarket following the announcement.
Cigna Group lifted its outlook and reported a higher profit in the second quarter, driven by growth in both its healthcare and pharmacy-benefit businesses.
Cigna Group will report its earnings on Thursday under its new chief executive, Brian Evanko. It’s transitioning its pharmacy benefits business to a rebate-free model.
Most S&P 500 investors assume they own the market, but one overlooked mechanism quietly determines how much cash actually flows back to shareholders, and ignoring it this year has carried a measurable price.
CI's Q2 earnings are likely to face pressure from fewer insured medical customers and a higher MCR despite expected revenue growth.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Cigna (CI), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
The healthcare giant looks expensive on today's numbers, but a patient investor is effectively buying it at a significant discount to that price.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
UnitedHealth's stock is flying high after it raised guidance, but on its latest earnings call, analysts zeroed in on an underlying margin divergence running right through the business.
The stock is trading near 52-week highs, but under the surface, commercial segment cost trends are creating headwinds.
Cigna Group (CI) continues to draw investor attention after recent share moves, with the stock last closing at US$281.45. The company’s mixed return profile over various periods is prompting closer scrutiny of its valuation and fundamentals. See our latest analysis for Cigna Group. Recent trading shows some cooling in momentum for Cigna Group, with the 1 day share price return slipping 0.83% and the 7 day return down 4.09%. The 5 year total shareholder return of 32.51% points to a steadier...
The sticker price on CVS shares looks high, but the real question is what it costs on the earnings expected two years from now.
The health insurer raised its forecast after a solid quarter, but investors focused on the one business so broken it’s forcing a strategic retreat.
Elevance Health raised its profit forecast and the stock promptly fell. Here’s the one number that explains why investors headed for the exits.
The stock is priced for strength, but a deep and persistent drag from one of its largest divisions could challenge the optimistic narrative.
The stock's current valuation looks steep, but for a patient holder, the price tag on future earnings tells a very different story.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
